{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:14Z","timestamp":1793502914037,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"OsteoRheuma Bern"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bone.2020.115830","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T22:58:47Z","timestamp":1608937127000},"page":"115830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study"],"prefix":"10.1016","volume":"144","author":[{"given":"J.","family":"Everts-Graber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Ziswiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115830_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115830_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","author":"Papapoulos","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0015","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","author":"Bone","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115830_bb0020","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2020.115830_bb0030","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115830_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","author":"Miller","year":"2008","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115830_bb0040","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-015-3459-5","article-title":"Multiple clinical vertebral fractures following denosumab discontinuation","author":"Anastasilakis","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0050","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","author":"Lamy","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2020.115830_bb0055","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","article-title":"Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports","volume":"30","author":"Lamy","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","author":"McClung","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2017","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115830_bb0080","doi-asserted-by":"crossref","unstructured":"Meier C, Uebelhart B, Aubry-Rozier B, et al. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO\/ASCO). Swiss Med Wkly. 2017;147. doi:https:\/\/doi.org\/10.4414\/smw.2017.14484.","DOI":"10.4414\/smw.2017.14484"},{"key":"10.1016\/j.bone.2020.115830_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X18805759","article-title":"New and emerging concepts in the use of denosumab for the treatment of osteoporosis","author":"Lewiecki","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bone.2020.115830_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","author":"Everts-Graber","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0095","article-title":"American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","author":"Camacho","year":"2020","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2020.115830_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115830_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","author":"Genant","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0110","series-title":"Concato J","author":"Peduzzi","year":"1995"},{"key":"10.1016\/j.bone.2020.115830_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","author":"Lehmann","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0120","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","author":"Horne","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115830_bb0125","doi-asserted-by":"crossref","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res. 2019. doi:https:\/\/doi.org\/10.1002\/jbmr.3853.","DOI":"10.1002\/jbmr.3853"},{"key":"10.1016\/j.bone.2020.115830_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","author":"Makras","year":"2020","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115830_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","author":"Reid","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115830_bb0140","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-019-00553-w","article-title":"Effect of zoledronate on bone loss after romosozumab\/denosumab: 2-year follow-up","author":"Horne","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2020.115830_bb0145","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","author":"S\u00f8lling","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0150","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","author":"Kendler","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115830_bb0155","unstructured":"Dickens et al. 2019 Oral vs intravenous bisphosphonates for preventing bone loss after denosumab discontinuation. J. Bone Miner. Res. 32 (Suppl 1). Available at https:\/\/www.asbmr.org\/education\/2019-abstracts."},{"key":"10.1016\/j.bone.2020.115830_bb0160","doi-asserted-by":"crossref","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","author":"Lamy","year":"2019","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2020.115830_bb0165","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz321","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study","author":"Lyu","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115830_bb0170","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115830_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115830_bb0180","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","author":"Uebelhart","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0185","article-title":"Prior exposure to bisphosphonates prevents the rebound of bone turnover markers after denosumab therapy","author":"Uebelhart","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115830_bb0190","doi-asserted-by":"crossref","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","author":"Bekker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.4022","article-title":"Zoledronate following denosumab discontinuation: partial reassurance but no confidence","author":"Ferrari","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2020.115830_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","author":"Gnant","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.bone.2020.115830_bb0210","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.56.GP59","article-title":"Thirty-one men and women with145 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study","author":"Elena","year":"2018","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.bone.2020.115830_bb0215","article-title":"Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors","author":"Gonzalez-Rodriguez","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.bone.2020.115830_bb0220","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2020.115830_bb0225","article-title":"Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study","author":"Rosen","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115830_bb0230","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220306189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220306189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:53:00Z","timestamp":1757613180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220306189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":46,"alternative-id":["S8756328220306189"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115830","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115830"}}